Sabina A Murphy

Summary

Affiliation: Brigham and Women's Hospital
Country: USA

Publications

  1. ncbi request reprint Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials)
    Sabina A Murphy
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 100:1047-51. 2007
  2. ncbi request reprint Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis
    Sabina A Murphy
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 350 Longwood Avenue, First Floor, Boston, MA 02115, USA
    Eur Heart J 28:2077-86. 2007
  3. ncbi request reprint Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombo
    Stephen D Wiviott
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, Mass 02115, USA
    Circulation 109:580-6. 2004
  4. ncbi request reprint A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22
    Stephen D Wiviott
    The TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Circulation 113:1406-14. 2006
  5. ncbi request reprint Association between thrombolysis in myocardial infarction myocardial perfusion grade, biomarkers, and clinical outcomes among patients with moderate- to high-risk acute coronary syndromes: observations from the randomized trial to evaluate the relative PR
    C Michael Gibson
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, MA, USA
    Am Heart J 152:756-61. 2006
  6. ncbi request reprint Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction
    C Michael Gibson
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 43:1170-6. 2004
  7. doi request reprint Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials)
    Emmanouil S Brilakis
    Cardiovascular Division, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    Am J Cardiol 102:552-8. 2008
  8. ncbi request reprint A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial
    C Michael Gibson
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
    J Am Coll Cardiol 47:2364-73. 2006
  9. ncbi request reprint Effects of pretreatment with clopidogrel on nonemergent percutaneous coronary intervention after fibrinolytic administration for ST-segment elevation myocardial infarction: a Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarct
    C Michael Gibson
    TIMI Study Group and Cardiovascular Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA
    Am Heart J 155:133-9. 2008
  10. ncbi request reprint Combined assessment of thrombolysis in myocardial infarction flow grade, myocardial perfusion grade, and ST-segment resolution to evaluate epicardial and myocardial reperfusion
    Robert P Giugliano
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, 350 Longwood Avenue, 1st Floor Offices, Boston, MA 02115, USA
    Am J Cardiol 93:1362-7, A5-6. 2004

Detail Information

Publications92

  1. ncbi request reprint Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials)
    Sabina A Murphy
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 100:1047-51. 2007
    ..On the basis of these findings, 1 death was prevented for every 95 patients treated with high-dose statin therapy for 2 years. The results of this pooled analysis provide further evidence for early intensive statin therapy after ACS...
  2. ncbi request reprint Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis
    Sabina A Murphy
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 350 Longwood Avenue, First Floor, Boston, MA 02115, USA
    Eur Heart J 28:2077-86. 2007
    ....
  3. ncbi request reprint Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombo
    Stephen D Wiviott
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, Mass 02115, USA
    Circulation 109:580-6. 2004
    ..We sought to examine the relationship between gender and cardiac biomarkers in patients with unstable angina (UA)/non-ST-segment elevation myocardial infarction (NSTEMI)...
  4. ncbi request reprint A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22
    Stephen D Wiviott
    The TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Circulation 113:1406-14. 2006
    ..We analyzed the design, implementation, and results of the two trials in an attempt to clarify the effects of early intensive statin therapy...
  5. ncbi request reprint Association between thrombolysis in myocardial infarction myocardial perfusion grade, biomarkers, and clinical outcomes among patients with moderate- to high-risk acute coronary syndromes: observations from the randomized trial to evaluate the relative PR
    C Michael Gibson
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, MA, USA
    Am Heart J 152:756-61. 2006
    ..A variety of imaging modalities have implicated impaired myocardial perfusion in the pathogenesis of acute coronary syndromes (ACSs)...
  6. ncbi request reprint Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction
    C Michael Gibson
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 43:1170-6. 2004
    ....
  7. doi request reprint Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials)
    Emmanouil S Brilakis
    Cardiovascular Division, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    Am J Cardiol 102:552-8. 2008
    ..In conclusion, compared with patients with ACS without previous CABG, those with previous CABG have a higher risk for adverse cardiac events and may derive similar benefit from intensive statin therapy...
  8. ncbi request reprint A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial
    C Michael Gibson
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
    J Am Coll Cardiol 47:2364-73. 2006
    ....
  9. ncbi request reprint Effects of pretreatment with clopidogrel on nonemergent percutaneous coronary intervention after fibrinolytic administration for ST-segment elevation myocardial infarction: a Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarct
    C Michael Gibson
    TIMI Study Group and Cardiovascular Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA
    Am Heart J 155:133-9. 2008
    ..We sought to evaluate the effect of nonemergent PCI on mortality among patients with STEMI treated with fibrinolytic administration and the consequence of clopidogrel pretreatment on this effect...
  10. ncbi request reprint Combined assessment of thrombolysis in myocardial infarction flow grade, myocardial perfusion grade, and ST-segment resolution to evaluate epicardial and myocardial reperfusion
    Robert P Giugliano
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, 350 Longwood Avenue, 1st Floor Offices, Boston, MA 02115, USA
    Am J Cardiol 93:1362-7, A5-6. 2004
    ..This new end point is proposed to evaluate the success of reperfusion therapy in patients who undergo early angiography...
  11. ncbi request reprint Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and th
    Marc S Sabatine
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    Circulation 109:874-80. 2004
    ..We sought to examine the effect of these advances on clinical outcomes and the benefits of an early invasive strategy in UA/NSTEMI...
  12. doi request reprint Prospective evaluation of pregnancy-associated plasma protein-a and outcomes in patients with acute coronary syndromes
    Marc P Bonaca
    Brigham and Women s Hospital, Boston, Massachusetts, USA
    J Am Coll Cardiol 60:332-8. 2012
    ..This study sought to investigate whether pregnancy-associated plasma protein-A (PAPP-A) is useful for risk assessment in non-ST-segment elevation acute coronary syndrome (NSTE-ACS)...
  13. ncbi request reprint Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial
    Marc S Sabatine
    Thrombolysis in Myocardial Infarction TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Circulation 112:3846-54. 2005
    ..Whether these advantages translate into greater infarct-related artery patency and fewer adverse clinical events in patients with ST-elevation myocardial infarction (STEMI) receiving fibrinolytic therapy remains under study...
  14. ncbi request reprint Evaluation of the association of proximal coronary culprit artery lesion location with clinical outcomes in acute myocardial infarction
    Juhana Karha
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Am J Cardiol 92:913-8. 2003
    ..In patients with a LAD culprit lesion, proximal lesion location is a multivariate correlate of adverse outcomes even after adjustment for coronary blood flow and other covariates...
  15. doi request reprint Association of impaired thrombolysis in myocardial infarction myocardial perfusion grade with ventricular tachycardia and ventricular fibrillation following fibrinolytic therapy for ST-segment elevation myocardial infarction
    C Michael Gibson
    TIMI Study Group, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 51:546-51. 2008
    ..The goal of this analysis was to evaluate the association of impaired Thrombolysis In Myocardial Infarction myocardial perfusion grade (TMPG) with sustained ventricular tachycardia (VT) or ventricular fibrillation (VF)...
  16. doi request reprint Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardi
    David A Morrow
    Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Circulation 119:2758-64. 2009
    ..This effect must be balanced against an increased bleeding risk. We aimed to characterize the effect of prasugrel with respect to the type, size, and timing of MI using the universal classification of MI...
  17. ncbi request reprint The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction: the ECG CLARITY-TIMI 28 Study
    Benjamin M Scirica
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 48:37-42. 2006
    ..This study was designed to determine the relationship between clopidogrel and early ST-segment resolution (STRes) and the interaction of the two with clinical outcomes after fibrinolysis...
  18. ncbi request reprint Sequential risk stratification using TIMI risk score and TIMI flow grade among patients treated with fibrinolytic therapy for ST-segment elevation acute myocardial infarction
    Dimitrios Karmpaliotis
    Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Am J Cardiol 94:1113-7. 2004
    ..High TRS at presentation is associated with abnormal myocardial perfusion, even after adjusting for possible confounders...
  19. doi request reprint Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolys
    Elliott M Antman
    Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 51:2028-33. 2008
    ....
  20. ncbi request reprint Association between platelet receptor occupancy after eptifibatide (integrilin) therapy and patency, myocardial perfusion, and ST-segment resolution among patients with ST-segment-elevation myocardial infarction: an INTEGRITI (Integrilin and Tenecteplase
    C Michael Gibson
    TIMI Study Group and the Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass, USA
    Circulation 110:679-84. 2004
    ....
  21. ncbi request reprint B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy
    Jessica L Mega
    TIMI Study Group, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 44:335-9. 2004
    ....
  22. ncbi request reprint Association of culprit lesion calcium with angiographic and clinical outcomes in patients with ST-elevation myocardial infarction treated with fibrinolytic therapy
    Ajay J Kirtane
    Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Am J Cardiol 95:337-42. 2005
    ..2, p = 0.045). CLC is independently associated with indexes of poorer epicardial flow and a higher incidence of adverse clinical outcomes after fibrinolytic administration in patients who have ST-elevation myocardial infarction...
  23. ncbi request reprint Impact of iodinated contrast injections on percent diameter coronary arterial stenosis and implications for trials of intracoronary pharmacotherapies in patients with ST-elevation myocardial infarction
    C Michael Gibson
    Cardiovascular Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 100:13-7. 2007
    ....
  24. ncbi request reprint Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction
    Masahisa Shimpo
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass, USA
    Circulation 109:2186-90. 2004
    ..Serum levels of ST2 are associated with prognosis in nonischemic heart failure, but the predictive value of ST2 in patients with acute myocardial infarction is unknown...
  25. ncbi request reprint Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary syndromes: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservati
    Marc S Sabatine
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    J Am Coll Cardiol 40:1761-8. 2002
    ....
  26. ncbi request reprint Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes
    James A de Lemos
    TIMI Study Group, Donald W Reynolds Cardiovascular Clinical Research Center, The University of Texas, Southwestern Medical School, Dallas, TX 75390 9047, USA
    Circulation 107:690-5. 2003
    ..MCP-1 appears to play a critical role at multiple stages in atherosclerosis, including the initiation of the fatty streak, promotion of plaque instability, and remodeling after myocardial infarction...
  27. ncbi request reprint Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction: B-type natriuretic peptide and prognosis in TACTICS-TIMI 18
    David A Morrow
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 41:1264-72. 2003
    ....
  28. ncbi request reprint Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)-TIMI 34 trial
    C Michael Gibson
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and the Department of Medicine, Harvard Medical School, Boston, MA, USA
    Am Heart J 152:668-75. 2006
    ..Early restoration of epicardial flow before primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI) has been associated with improved clinical outcomes...
  29. doi request reprint Relations between bleeding and outcomes in patients with ST-elevation myocardial infarction in the ExTRACT-TIMI 25 trial
    Robert P Giugliano
    Cardiovascular Medicine, TIMI Study Group, Brigham and Women s Hospital, 350 Longwood Avenue, 1st Floor Offices, Boston, MA 02115, USA
    Eur Heart J 31:2103-10. 2010
    ..To evaluate the association of bleeding with mortality in ST-elevation myocardial infarction (STEMI)...
  30. doi request reprint Association of non-steroidal anti-inflammatory drugs with outcomes in patients with ST-segment elevation myocardial infarction treated with fibrinolytic therapy: an ExTRACT-TIMI 25 analysis
    C Michael Gibson
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 350 Longwood Avenue, First Floor, Boston, MA 02115, USA
    J Thromb Thrombolysis 27:11-7. 2009
    ....
  31. ncbi request reprint Predicting a late positive serum troponin in initially troponin-negative patients with non-ST-elevation acute coronary syndrome: clinical predictors and validated risk score results from the TIMI IIIB and GUSTO IIA studies
    James L Januzzi
    Cardiology Division, Massachusetts General Hospital, Boston, MA 02114, USA
    Am Heart J 151:360-6. 2006
    ..Troponin testing is useful for evaluating patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS); however, a significant percentage of patients are troponin negative at presentation and develop late rise of the marker...
  32. ncbi request reprint Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction
    Elliott M Antman
    Thrombolysis in Myocardial Infarction TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 354:1477-88. 2006
    ..Unfractionated heparin is often used as adjunctive therapy with fibrinolysis in patients with ST-elevation myocardial infarction. We compared a low-molecular-weight heparin, enoxaparin, with unfractionated heparin for this purpose...
  33. doi request reprint Clinical features and outcomes of women with unstable ischemic heart disease: observations from metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndromes-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36)
    Jessica L Mega
    Brigham and Women s Hospital, 350 Longwood Ave, 1st Floor, Boston, MA 02115, USA
    Circulation 121:1809-17. 2010
    ..In prior studies, sex-based treatment differences have been observed with the antiischemic ranolazine, with a possibly diminished effect in women...
  34. ncbi request reprint Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes
    Michelle O'Donoghue
    Cardiovascular Division, Brigham and Women s Hospital, 350 Longwood Ave, First Floor, Boston, Mass 02115, USA
    Circulation 114:550-7. 2006
    ..Although it has been investigated as an early marker of acute myocardial infarction, its prognostic utility in acute coronary syndromes has not been established...
  35. ncbi request reprint Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction)
    Michelle O'Donoghue
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Circulation 113:1745-52. 2006
    ..The prognostic value of Lp-PLA2 in patients with acute coronary syndromes (ACS) has not been established...
  36. doi request reprint Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection T
    Sabina A Murphy
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    J Am Coll Cardiol 54:2358-62. 2009
    ....
  37. doi request reprint Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial
    Sean R Wilson
    Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    J Am Coll Cardiol 53:1510-6. 2009
    ..We aimed to evaluate the efficacy and safety of ranolazine in a larger and more diverse group of patients with angina than previously studied...
  38. pmc Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18
    David A Morrow
    TIMI Study Group Cardiovascular Division, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Eur Heart J 29:1096-102. 2008
    ....
  39. ncbi request reprint Effect of enoxaparin versus unfractionated heparin in diabetic patients with ST-elevation myocardial infarction in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRAC
    David A Morrow
    Department of Medicine, Harvard Medical School, Boston, MA, USA
    Am Heart J 154:1078-84, 1084.e1. 2007
    ..Potent antithrombotic therapies may offer particular benefit for these high-risk patients and must be balanced against the potential for increased bleeding...
  40. ncbi request reprint Association of epicardial and tissue-level reperfusion with left ventricular end-diastolic pressures in ST-elevation myocardial infarction
    Ajay J Kirtane
    Department of Medicine, Beth Israel Deaconess Medical Center, USA
    J Thromb Thrombolysis 17:177-84. 2004
    ..8, p = 0.02) and 30-day congestive heart failure (OR 4.4, p = 0.02). In STEMI, angiographic indices of incomplete reperfusion are associated with an elevated LVEDP, and elevated LVEDP is associated with adverse clinical outcomes...
  41. ncbi request reprint Time for contrast material to traverse the epicardial artery and the myocardium in ST-segment elevation acute myocardial infarction versus unstable angina pectoris/non-ST-elevation acute myocardial infarction
    Graham C Wong
    TIMI Study Group and the Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 91:1163-7. 2003
    ..These data provide insight into potential mechanistic differences between these 2 clinical syndromes...
  42. ncbi request reprint Association of the timing of ST-segment resolution with TIMI myocardial perfusion grade in acute myocardial infarction
    C Michael Gibson
    TIMI Study Group, The Department of Medicine, Brigham and Women s Hospital, Boston, Mass, USA
    Am Heart J 147:847-52. 2004
    ..However, no data exist comparing the speed of ST resolution on continuous electrocardiogram (ECG) monitoring with the TMPG on coronary angiography. We hypothesized that delayed ST res is associated with impaired TMPGs...
  43. ncbi request reprint Correlates of bleeding events among moderate- to high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide: observations from the PROTECT-TIMI-30 trial
    Ajay J Kirtane
    Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, USA
    J Am Coll Cardiol 47:2374-9. 2006
    ..We aimed to identify correlates of Thrombolysis In Mycocardial Infarction (TIMI) major/minor bleeding among eptifibatide-treated patients undergoing percutaneous coronary intervention (PCI)...
  44. ncbi request reprint Prasugrel versus clopidogrel in patients with acute coronary syndromes
    Stephen D Wiviott
    Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 357:2001-15. 2007
    ..Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention...
  45. ncbi request reprint Influence of race on death and ischemic complications in patients with non-ST-elevation acute coronary syndromes despite modern, protocol-guided treatment
    Marc S Sabatine
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Mass 02115
    Circulation 111:1217-24. 2005
    ..Whether the disparate outcomes exist independently of potential biases in treatment patterns remains unclear...
  46. ncbi request reprint Relation of impaired Thrombolysis In Myocardial Infarction myocardial perfusion grades to residual thrombus following the restoration of epicardial patency in ST-elevation myocardial infarction
    Ajay J Kirtane
    Department of Medicine, Beth Israel Deaconess Medical Center, and TIMI Study Group, Brigham and Women s Hospital, Harvard Medical School, Cambridge, MA, USA
    Am J Cardiol 95:224-7. 2005
    ..043). In multivariate analyses, angiographically evident thrombus was associated with higher corrected TIMI frame counts and worsened myocardial perfusion independent of clinical and angiographic covariates, including TIMI grade 3 flow...
  47. ncbi request reprint Benefit of an early invasive management strategy in women with acute coronary syndromes
    Ruchira Glaser
    Department of Medicine, University of Pennsylvania, Philadelphia, USA
    JAMA 288:3124-9. 2002
    ..However, these studies were performed prior to the widespread use of platelet glycoprotein IIb/IIIa inhibitors and intracoronary stents...
  48. ncbi request reprint C-reactive protein and cardiovascular outcomes in smokers versus nonsmokers in non-ST-elevation acute coronary syndrome (from the TACTICS-TIMI 18 trial)
    Nazanin Moghbeli
    Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 96:635-8. 2005
    ..0 vs 5.1 mg/L, p <0.001). CRP was associated with adverse cardiovascular outcomes in smokers and nonsmokers, even when adjusted for the presence of pulmonary disease...
  49. ncbi request reprint Angiographic perfusion score: an angiographic variable that integrates both epicardial and tissue level perfusion before and after facilitated percutaneous coronary intervention in acute myocardial infarction
    C Michael Gibson
    TIMI Study Group, The Department of Medicine, Brigham and Women s Hospital, Boston, Mass, USA
    Am Heart J 148:336-40. 2004
    ....
  50. doi request reprint Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial
    David A Morrow
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Circulation 119:2032-9. 2009
    ..We designed a prospective evaluation of the effect of ranolazine on hyperglycemia as part of a randomized, double-blind, placebo-controlled outcomes trial...
  51. doi request reprint Impact of saphenous vein graft radiographic markers on clinical events and angiographic parameters
    Stephen A Olenchock
    Cardiothoracic Surgery Department, Tufts University School of Medicine and Caritas St Elizabeth s Medical Center, Boston, Massachusetts, USA
    Ann Thorac Surg 85:520-4. 2008
    ..The goal of the present analysis was to evaluate the association of SVG markers with clinical outcomes and graft patency...
  52. ncbi request reprint Evaluation of the AccuTnI cardiac troponin I assay for risk assessment in acute coronary syndromes
    David A Morrow
    Department of Medicine and TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    Clin Chem 49:1396-8. 2003
  53. doi request reprint The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Pla
    Michelle O'Donoghue
    TIMI Study Group, Brigham and Women s Hospital, Boston, MA 02115, USA
    J Am Coll Cardiol 54:678-85. 2009
    ..We evaluated the efficacy and safety of prasugrel and clopidogrel in the setting of a glycoprotein (GP) IIb/IIIa inhibitor...
  54. ncbi request reprint Hemodynamic significance of periprocedural myocardial injury assessed with N-terminal pro-B-type natriuretic peptide after percutaneous coronary intervention in patients with stable and unstable coronary artery disease (from the JUMBO-TIMI 26 trial)
    Marc P Bonaca
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Am J Cardiol 99:344-8. 2007
    ..This finding supports the physiologic relevance of procedural MI and the continued effort to define therapies that decrease the risk of this complication...
  55. doi request reprint Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial I
    Stephen D Wiviott
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    Circulation 118:1626-36. 2008
    ..We compared prasugrel with clopidogrel among subjects with DM in TRITON-TIMI 38...
  56. ncbi request reprint Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischem
    Benjamin M Scirica
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, and Harvard Medical School, 75 Francis St, Boston, MA 02115, USA
    Circulation 116:1647-52. 2007
    ..Ranolazine reduces proarrhythmic substrate and triggers such as early afterdepolarization in experimental models. However, the potential antiarrhythmic actions of ranolazine have yet to be demonstrated in humans...
  57. ncbi request reprint Angiographically evident thrombus following fibrinolytic therapy is associated with impaired myocardial perfusion in STEMI: a CLARITY-TIMI 28 substudy
    Ajay J Kirtane
    Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Eur Heart J 27:2040-5. 2006
    ..The presence of residual thrombus following fibrinolytic therapy for ST-segment elevation myocardial infarction (STEMI) may predispose to greater embolization and microvascular dysfunction...
  58. ncbi request reprint Serum blood urea nitrogen as an independent marker of subsequent mortality among patients with acute coronary syndromes and normal to mildly reduced glomerular filtration rates
    Ajay J Kirtane
    Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts
    J Am Coll Cardiol 45:1781-6. 2005
    ..We hypothesized that elevated blood urea nitrogen (BUN) would be associated with adverse outcomes independent of serum creatinine (sCr)-based estimates of kidney function in patients with acute coronary syndromes (ACS)...
  59. ncbi request reprint Association of duration of symptoms at presentation with angiographic and clinical outcomes after fibrinolytic therapy in patients with ST-segment elevation myocardial infarction
    C Michael Gibson
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts, USA
    J Am Coll Cardiol 44:980-7. 2004
    ....
  60. ncbi request reprint Comparison of effects of bare metal versus drug-eluting stent implantation on biomarker levels following percutaneous coronary intervention for non-ST-elevation acute coronary syndrome
    C Michael Gibson
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 97:1473-7. 2006
    ..In conclusion, patients undergoing DES implantation achieved more reductions in periprocedural markers of inflammation and necrosis than patients receiving bare metal stents among those with non-ST-elevation acute coronary syndrome...
  61. ncbi request reprint Association of a history of systemic hypertension with mortality, thrombotic, and bleeding complications following non-ST-segment elevation acute coronary syndrome
    Raphaelle Dumaine
    Thrombolysis in Myocardial Infarction TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, and Harvard Medical School, Boston, MA 02115, USA
    J Clin Hypertens (Greenwich) 8:315-22. 2006
    ..45, 95% CI 1.03-2.06; p=0.036 at 30 days). It was concluded that chronic hypertension remains an independent marker for major short- and long-term cardiac adverse outcomes after non-ST-segment elevation acute coronary syndrome...
  62. ncbi request reprint Association between duration of tirofiban therapy before percutaneous intervention and tissue level perfusion (a TACTICS-TIMI 18 substudy)
    C Michael Gibson
    Department of Medicine, Brigham and Women s Hospital, 350 Longwood Avenue, Boston, MA 02115, USA
    Am J Cardiol 94:492-4. 2004
    ....
  63. ncbi request reprint Association of prerandomization anticoagulant switching with bleeding in the setting of percutaneous coronary intervention (A REPLACE-2 analysis)
    C Michael Gibson
    Cardiovascular Division, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Am J Cardiol 99:1687-90. 2007
    ....
  64. ncbi request reprint Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrel
    Marc S Sabatine
    Thrombolysis in Myocardial Infarction TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 49:2256-63. 2007
    ....
  65. doi request reprint Clinical, procedural, and pharmacologic correlates of acute and subacute stent thrombosis: results of a multicenter case-control study with 145 thrombosis events
    Michael J Rinaldi
    Beth Israel Deaconess Medical Center, Boston, MA, USA
    Am Heart J 155:654-60. 2008
    ....
  66. ncbi request reprint Angiographic and clinical characteristics associated with the development of Q-wave and non-Q-wave myocardial infarction in the thrombolysis in myocardial infarction (TIMI) 14 trial
    Sabina A Murphy
    TIMI Study Group, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Am Heart J 146:42-7. 2003
    ....
  67. ncbi request reprint Prognosis in the thrombolysis in myocardial ischemia III registry according to the Braunwald unstable angina pectoris classification
    Benjamin M Scirica
    Cardiovascular Division, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Am J Cardiol 90:821-6. 2002
    ..Given their high risk for adverse events, patients with secondary UAP should be treated aggressively...
  68. ncbi request reprint Administration of intracoronary eptifibatide during ST-elevation myocardial infarction
    Duane S Pinto
    Beth Israel Deaconess Medical Center, Division of Cardiology, Boston, Massachusetts, USA
    Am J Cardiol 96:1494-7. 2005
    ..Further prospective randomized trials are warranted to evaluate the efficacy and safety of intracoronary eptifibatide...
  69. ncbi request reprint Minimal ST-segment deviation: a simple, noninvasive method for identifying patients with a patent infarction-related artery after fibrinolytic administration
    Howard A Cooper
    Cardiovascular Division, Brigham and Women s Hospital, Boston, Mass 02115, USA
    Am Heart J 144:790-5. 2002
    ..The sum of ST-segment resolution (sum-STRES) has a high positive predictive value (PPV) for a patent IRA, but is quite time-consuming...
  70. ncbi request reprint Cost-effectiveness of coronary stenting and abciximab for patients with acute myocardial infarction: results from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) trial
    Ameet Bakhai
    Harvard Clinical Research Institute, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, Mass 02215, USA
    Circulation 108:2857-63. 2003
    ..Both stenting and the glycoprotein IIb/IIIa inhibitor abciximab improve outcomes for patients undergoing primary angioplasty for acute myocardial infarction (AMI). However, the cost-effectiveness of these strategies is unknown...
  71. ncbi request reprint Validated risk score predicts the development of congestive heart failure after presentation with unstable angina or non-ST-elevation myocardial infarction: results from OPUS-TIMI 16 and TACTICS-TIMI 18
    John V Wylie
    Division of Cardiology, Beth Israel Deaconess Medical Center, Department of Medicine, Harvard Medical School, Boston, Mass 02215, USA
    Am Heart J 148:173-80. 2004
    ..We developed and validated a risk score to predict which patients will develop CHF...
  72. ncbi request reprint Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial
    C Michael Gibson
    Cardiovascular Division, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    J Am Coll Cardiol 49:2238-46. 2007
    ....
  73. doi request reprint Association of blood glucose with angiographic and clinical outcomes among patients with ST-segment elevation myocardial infarction (from the CLARITY-TIMI-28 study)
    Duane S Pinto
    Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 101:303-7. 2008
    ..IRA patency after fibrinolytic administration is related to admission glucose independent of clopidogrel administration...
  74. ncbi request reprint TIMI myocardial perfusion grade and ST segment resolution: association with infarct size as assessed by single photon emission computed tomography imaging
    Brad G Angeja
    Department of Medicine, The University of California, San Francisco, USA
    Circulation 105:282-5. 2002
    ..0001). The difference in infarct size by TMPG persisted when stratified by category of ST resolution...
  75. ncbi request reprint The relationship of intracoronary stent placement following thrombolytic therapy to tissue level perfusion
    C Michael Gibson
    Harvard Clinical Research Institute, Boston, MA 02215, USA
    J Thromb Thrombolysis 13:63-8. 2002
    ..Stenting has been shown to improve lumen diameters and thereby improve epicardial blood flow, but the impact of stent placement on tissue level perfusion has not been well characterized...
  76. doi request reprint Distribution of traditional and novel risk factors and their relation to subsequent cardiovascular events in patients with acute coronary syndromes (from the PROVE IT-TIMI 22 trial)
    Subroto Acharjee
    Department of Medicine, SUNY at Buffalo School of Medicine, Buffalo, New York, USA
    Am J Cardiol 105:619-23. 2010
    ....
  77. doi request reprint Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis
    Michelle O'Donoghue
    TIMI Study Group, Brigham and Women s Hospital, 350 Longwood Ave, First Floor, Boston, MA 02115, USA
    JAMA 300:71-80. 2008
    ..Although an invasive strategy is frequently used in patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS), data from some trials suggest that this strategy may not benefit women...
  78. ncbi request reprint Association of peripheral neutrophilia with adverse angiographic outcomes in ST-elevation myocardial infarction
    Ajay J Kirtane
    Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA
    Am J Cardiol 93:532-6. 2004
    ..In patients with ST-elevation myocardial infarction, absolute and relative neutrophilia were associated with impaired epicardial and microvascular perfusion...
  79. ncbi request reprint Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial
    Stephen D Wiviott
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital, Department of Medicine, Harvard Medical School, Boston, Mass 02115, USA
    Circulation 111:3366-73. 2005
    ..Prasugrel (CS-747, LY640315), a novel potent thienopyridine P2Y(12) receptor antagonist, has the potential to achieve higher levels of inhibition of ADP-induced platelet aggregation than currently approved doses of clopidogrel...
  80. ncbi request reprint TIMI risk index and the benefit of enoxaparin in patients with ST-elevation myocardial infarction
    Christian T Ruff
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Mass 02115, USA
    Am J Med 120:993-8. 2007
    ....
  81. ncbi request reprint Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial
    Stephen D Wiviott
    Brigham and Women s Hospital, Cardiovascular Division, 75 Francis St, Boston, MA 02115, USA
    Circulation 116:2923-32. 2007
    ..The relative antiplatelet effects of prasugrel versus high-dose clopidogrel in percutaneous coronary intervention patients are unknown...
  82. ncbi request reprint Myonecrosis following stent placement: association between impaired TIMI myocardial perfusion grade and MRI visualization of microinfarction
    James W Choi
    Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
    Catheter Cardiovasc Interv 61:472-6. 2004
    ..03). These data support the theory that distal embolization and microvascular obstruction are associated with myonecrosis following otherwise successful coronary stent placement and provide further insight into its pathophysiology...
  83. ncbi request reprint Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes
    Richard C Becker
    Cardiovascular Thrombosis Research Center, Division of Cardiology, University of Massachusetts Medical School, Boston 01655, USA
    Am Heart J 143:753-9. 2002
    ..Although emerging data suggest that low-molecular weight preparations offer distinct advantages over unfractionated heparin, limited information on patient-related factors that may influence dosing, safety, and efficacy is available...
  84. ncbi request reprint Association between blood glucose and long-term mortality in patients with acute coronary syndromes in the OPUS-TIMI 16 trial
    Satish Bhadriraju
    McLaren Regional Medical Center Michigan State University, Flint, Michigan, USA
    Am J Cardiol 97:1573-7. 2006
    ..Glucose levels during ACS may be an important addition to the risk stratification of patients with ACS and a potentially important target for therapy...
  85. ncbi request reprint The prognostic value of serum myoglobin in patients with non-ST-segment elevation acute coronary syndromes. Results from the TIMI 11B and TACTICS-TIMI 18 studies
    James A de Lemos
    Thrombolysis in Myocardial Infarction TIMI Study Group, Reynolds Cardiovascular Clinical Research Center, University of Texas Southwestern Medical School, 5323 Harry Hines Boulevard, Dallas, TX 75390 9047, USA
    J Am Coll Cardiol 40:238-44. 2002
    ..The goal of this study was to define the prognostic value of serum myoglobin in patients with non-ST-elevation acute coronary syndromes (ACS)...
  86. ncbi request reprint Quantitative comparison of coronary artery flow and myocardial perfusion in patients with acute myocardial infarction in the presence and absence of recent cocaine use
    Jim Edward Weber
    The University of Michigan, Department of Emergency Medicine and Hurley Medical Center, USA
    J Thromb Thrombolysis 14:239-45. 2002
    ..We hypothesized that significant angiographic differences exist between CAMI patients vs thrombotic AMI patients (TAMI) and normal controls...
  87. ncbi request reprint Intracoronary bolus administration of eptifibatide during percutaneous coronary stenting for non ST elevation myocardial infarction and unstable angina
    Albert J Deibele
    Division of Cardiology, Duluth Clinic, Duluth, Minnesota, USA
    J Thromb Thrombolysis 22:47-50. 2006
    ....
  88. doi request reprint Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial
    Michael Miller
    Division of Cardiology, University of Maryland Medical Center, Baltimore, Maryland 21201, USA
    J Am Coll Cardiol 51:724-30. 2008
    ..The purpose of this study was to assess the impact of on-treatment triglycerides (TG) on coronary heart disease (CHD) risk after an acute coronary syndrome (ACS)...
  89. ncbi request reprint Infarct-related coronary artery patency and medication use prior to ST-segment elevation myocardial infarction
    Christina R Robinson
    The Department of Internal Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
    Am J Cardiol 97:7-9. 2006
    ..Further, our data demonstrate a graded association according to the number of such medications being administered: the likelihood of a patent infarct-related artery increased to >50% as the number of these medications increased...
  90. ncbi request reprint Early cardiac catheterization is associated with lower mortality only among high-risk patients with ST- and non-ST-elevation acute coronary syndromes: observations from the OPUS-TIMI 16 trial
    Warren J Cantor
    Department of Medicine, Division of Cardiology, St Michael s Hospital, University of Toronto, Toronto, Ontario, Canada
    Am Heart J 149:275-83. 2005
    ..The benefit of catheterization in both syndromes may depend on patient risk for adverse clinical outcomes...
  91. ncbi request reprint Diminution in flow following primary stenting in the INAMI study
    Sabina A Murphy
    Catheter Cardiovasc Interv 59:417; author reply 417-8. 2003
  92. ncbi request reprint Single lead ST-segment recovery: a simple, reliable measure of successful fibrinolysis after acute myocardial infarction
    Mushabbar A Syed
    Henry Ford Heart and Vascular Institute, Detroit, Mich 48202, USA
    Am Heart J 147:275-80. 2004
    ..Among the different electrocardiographic markers of reperfusion, sum ST resolution is considered the hallmark of reperfusion, but is cumbersome to use...